Capital Markets Day: Commercial Execution and Innovation in Obesity Care slide image

Capital Markets Day: Commercial Execution and Innovation in Obesity Care

Commercial execution / Innovation and therapeutic focus Closing remarks Large unmet medical need within obesity and WegovyⓇ holds potential to unlock market Expectation to meet US WegovyⓇ demand in H2 2022 Pipeline positions Novo Nordisk for continued leadership SELECT interim analysis expected in 2022 Strategic aspiration is now sales of more than DKK 25 billion by 2025 novo nordisk MICHAEL PETERSEN Michael lives with obesity Denmark
View entire presentation